- Lobbying
- medicines
Lobbying Arrangements Results for 'Medicines'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Generic Drug Settlements S.316, Preserve Access to Affordable Generics Act. H.R. 1902, Protecting Consumer Access to Generic Drugs Act of 2007. H.R. 3161, S. 1859, Funding for the Office of Generi... |
BARR PHARMACEUTICALS, INC (formerly Barr Laboratories, Inc.)
|
Clark Lytle & Geduldig | |||
Details Advise client on legislative and administrative policy-making related to the biopharmaceutical industry generally, and client priorities specifically. Includes raising awareness amongst public offi... |
Roivant Sciences, Inc.
|
BGR Government Affairs | |||
Details Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medic... |
Perrigo, Inc.
|
FTI Government Affairs | |||
Details Issues related to domestic manufacturing of pharmaceuticals. |
Alvogen
|
Arnold & Porter Kaye Scholer LLP | |||
Details Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B... |
Merck & Co., Inc
|
Tiber Creek Group | |||
Details Recognizing pharmacists as providers within Medicare COVID-19 response; H.R. 1319- American Rescue Plan Act of 2021 (Public Law No. 117-2); H.R. 2670-National Defense Authorization Act For Fiscal Y... |
Cencora, Inc. (Formerly AmerisourceBergen Corporation)
|
Ballard Spahr LLP | |||
Details Education regarding H.R.6465-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act) Issues related to the Medicaid Drug Rebate Program proposed rule, gene therapies, and ... |
CSL Behring LLC
|
in-house lobbying | |||
Details Outreach to Senate HELP committee and House energy & Commerce seeking support for grant research grant efforts with HHS agencies. Outreach to BARDA, DoD, VHA and Assistant Secretary of Health for P... |
SaNOtize Research & Development Corporation
|
MR. DAVID GENCARELLI | |||
Details FDA and DEA regulation of cannabidiol; monitor S. 1333 (Therapeutic Hemp Medical Access Act of 2015), HR 1635 (Charlotte's Web Medical Access Act of 2015), S. 683/S. 1538 (Compassionate Access, Res... |
GW Pharma Inc.
|
SIDLEY AUSTIN LLP | |||
Details Issues related to the impact of the bio-pharmaceutical industry on the economy. Issues related to access to medicines and other medical therapies, the development of new medical therapies and regul... |
PhRMA (on behalf of We Work For Health)
|
MCBEE STRATEGIC CONSULTING, LLC. | |||
Details medical innovation; access to medicines; NIH funding |
Council for American Medical Innovation (CAMI)
|
Gephardt Group Government Affairs | |||
Details General issues related to opioid abuse and access to medication assisted treatment. |
Healthcare Distribution Alliance
|
Thorsen French Advocacy LLC | |||
Details Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; Proposals related to drug pric... |
Takeda Pharmaceuticals America, Inc.
|
ALPINE GROUP PARTNERS, LLC. | |||
Details General issues related to Over-The-Counter (OTC) pharmaceutical supply chain. Issues related to Drug Enforcement Administration Pseudoephedrine quotas. Issues related to the expansion of Flexible ... |
Consumer Healthcare Products Association
|
Kountoupes Denham Carr & Reid, LLC | |||
Details Animal health , issues impacting medicines and vaccines for animals; ADUFA Reauthorization. (H.R. 1418; S. 1844, H.R. 5860). Monitor issues related to general corporate taxation; issues related to ... |
Zoetis
|
Williams and Jensen, PLLC | |||
Details Advocate on behalf of pharmaceutical benefit management practices impacted by direct and indirect remuneration and point of sale rebates related to the Medicare Part D prescription drug benefit pro... |
CVS Caremark
|
The D Major Group | |||
Details H.R. 1038, Access to Life-Saving Medicine Act H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007 H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007 S. 1505, Afford... |
AMYLIN
|
MEHLMAN VOGEL CASTAGNETTI, INC. | |||
Details Highlight Antheia's use of synthetic biology to produce active pharmaceutical ingredients, support initiatives that expand domestic production capabilities of API, and educate lawmakers on various ... |
Antheia
|
Invariant LLC | |||
Details Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform Dextromethorphan Legislation related to reducing incidents of... |
Consumer Healthcare Products Association
|
BROWNSTEIN HYATT FARBER SCHRECK, LLP | |||
Details Proposals to enhance intellectual property protections to meet unmet medical needs, notably research and development of life-saving therapies; proposals to modify the Food Drug and Cosmetic Act whi... |
Allergan USA, Inc.
|
in-house lobbying | |||
Details General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process;... |
Vertex Pharmaceuticals Incorporated
|
in-house lobbying | |||
Details Ag-appropriations language related to labeling issues Drug Affordability and Access Issues 21st Century Cures Initiative and Related Legislative Proposals Advanced Medicines Initiative HR 2841, FAS... |
Generic Pharmaceutical Association
|
BOCKORNY GROUP, INC. | |||
Details Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug ... |
WYETH (FORMERLY AMERICAN HOME PRODUCTS)
|
Williams & Jensen, PLLC. | |||
Details Discussions related to health care reform, access to health care, drug pricing, PDUFA Reauthorization, and international access to medicines; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169)... |
AbbVie Inc.
|
Ogilvy Government Relations | |||
Details Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Legislation that would perm... |
Cencora Inc. (formerly AmerisourceBergen Corporation)
|
Kountoupes Denham Carr & Reid, LLC | |||
Details HR 5397 the Joe Fiandra Access to Home Infusion Act, Issues related to patient access to rare disease therapies, HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 the Consolidated Ap... |
Chiesi USA, Inc.
|
SPLITOAK STRATEGIES LLC | |||
Details Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH fund... |
Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.)
|
TCH Group, LLC | |||
Details drug shortages, critical medicines related to antibiotics and antimicrobials |
Amneal Pharmaceuticals, Inc.
|
TARPLIN, DOWNS & YOUNG, LLC | |||
Details S.150 - Affordable Prescriptions for Patients Act of 2023 Pandemic and All Hazards Preparedness Act Reauthorization Over-the-Counter access to oral contraception OTC Switch - general advocacy on ... |
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION
|
in-house lobbying | |||
Details Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Implementation of PL 114-328, Comprehensi... |
Safe Rx
|
Brownstein, Hyatt, Farber, Schreck, LLP | |||
Details Auto Industry Issues (General) Issues related to G.M. restructuring (S.1253, H.R. 2743, S.1304) [All other issues listed in more specific categories] Fiscal 2010 DOT Appropriations Fiscal 2010 Ener... |
GENERAL MOTORS CORPORATION
|
in-house lobbying | |||
Details Tobacco Cessation; E-cigarette regulation; S. 2622 - Quit Because of COVID Act; H.R. 5546 - PROTECT Act; H.R. 6286 - Clarifying Authority Over Nicotine Act. Dietary Supplement Eligible Expenses und... |
GlaxoSmithKline Consumer Healthcare
|
Faegre Drinker Biddle & Reath LLP | |||
Details MTB/GSP: update and modernize MTB so that it works for America and does not hinder American manufacturing; De minimis: reforming the threshold that hurts domestic manufacturing and overburdens our... |
COALITION FOR A PROSPEROUS AMERICA
|
in-house lobbying | |||
Details IRA implementation, Medicare & Medicaid payment and coverage issues IRA implementation, drug pricing and access, transparency, 340B, PAPHA reauthorization Federal budget issues |
Genentech, Inc.
|
TARPLIN, DOWNS & YOUNG, LLC | |||
Details Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public L... |
Healthcare Distribution Alliance (FORMERLY - HDMA)
|
Healthcare Distribution Alliance(HDA)(FORMERLY Healthcare Distribution Management Association (HDMA) | |||
Details IRA implementation, Medicare & Medicaid payment and coverage issues H.R. 5378: Lower Costs, More Transparency Act IRA implementation, prescription drug access and affordability, pricing, transpare... |
Bristol Myers Squibb
|
TARPLIN, DOWNS & YOUNG, LLC | |||
Details H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H. R. 5629, Pathway for Biosimi... |
Mattoon & Associates, LLC
|
PODESTA GROUP, INC. | |||
Details CBO modeling Drug Pricing Fiscal year 2024 Appropriations H.R. 5376, Inflation Reduction Act H.R. 6363, the Further Continuing Appropriations and Other Extensions Act, 2024 Importation Value of Med... |
NOVARTIS
|
in-house lobbying | |||
Details Implementation of Inflation Reduction Act of 2022. Drug shortages. S. 775 - Increasing Transparency in Generic Drug Applications Act. |
Association of Accessible Medicines
|
Mehlman Consulting, Inc. | |||
Details Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Proposals related to amend... |
Takeda Pharmaceuticals America, Inc.
|
in-house lobbying | |||
Details Issues related to FDA and HHS program funding for the FY24 Labor, HHS, Education and Related Agencies, and FY24 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies... |
GENENTECH, INC
|
in-house lobbying | |||
Details Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimburs... |
Genentech
|
Capitol Counsel LLC | |||
Details Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/ Excise Tax PDUFA Pandemic Preparedness/PAHPA Medicare Part D Rebate Reform- PBMs Out-Of-Pocket C... |
PFIZER INC.
|
in-house lobbying | |||
Details Issues related to the Improving Seniors Timely Access to Care Act of 2021; Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Techni... |
The Cigna Group and subsidiaries (Formerly Cigna Corporation and subsidiaries)
|
in-house lobbying | |||
Details Advance the use of and access to FDA-approved medications to treat addiction and mental illness in criminal justice and public health settings; pharmaceutical supply chain issues; drug pricing. Imp... |
Alkermes, Inc.
|
Crossroads Strategies, LLC | |||
Details General education about the generic and biosimilar pharmaceutical industry, including issues related to pricing and access. Issues related to the pharmaceutical supply chain. Issues related to dru... |
Association for Accessible Medicines (Formerly - Generic Pharmaceutical Assn)
|
Kountoupes Denham Carr & Reid, LLC | |||
Details Issues related to drug pricing, drug shortages, and the drug supply chain, including support for the following bills: the Protecting Patients Against PBM Abuses Act (H.R. 2880), the Transparency an... |
American Society of Health-System Pharmacists
|
in-house lobbying | |||
Details Issues related to onshoring supply chains and biomanufacturing of essential medicines to the United States. |
Centrient Pharmaceuticals LLC
|
AKIN GUMP STRAUSS HAUER & FELD | |||
Details Issues related to drug pricing reform -Changes to Public law 117-1769 Inflation Reduction Act -Awareness of implications to patients and research and development of Public law 117-1769 Inflation ... |
Amgen, Inc.
|
in-house lobbying | |||
Details Monitoring efforts involving patents and prescription drugs. Monitoring efforts involving patents and prescription drugs. Promoting access to biosimilars. S.2891 - Restoring America Invents Act. |
Alvotech USA, Inc.
|
Mehlman Castagnetti Rosen & Thomas, Inc. |